Ocugen Q3 revenue beats expectations, net loss narrows
OCGN•Ocugen reported Q3 revenue of $1.95 million, above the $1.10 million consensus estimate, and net loss per share narrowed to $0.01 from $0.07 a year earlier. The company expects cash to last into 2028.
1. Quarterly results
Q3 revenue was $1.95 million, beating the $1.10 million consensus estimate. Net loss was $3.60 million, or $0.01 per share, compared with a loss of $0.07 per share a year earlier. Operating expenses rose slightly to $19.70 million as higher research and development spending was partly offset by lower general and administrative costs.
2. Clinical and licensing updates
Ocugen received provisional approval for OCU400 in The Bahamas and signed a licensing deal for the Middle East and North Africa. It expects OCU400 Phase 3 topline data in Q1 2027, followed by a planned BLA submission. OCU410ST Phase 2/3 topline data are anticipated in Q2 2027, with a BLA submission planned.
